Compare Nucor Corporation (NUE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs TG Therapeutics Inc — how do they compare? Nucor Corporation trades at $271.79 (market cap $61.93B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Nucor Corporation is far larger — about 8.1× TG Therapeutics Inc's market cap, and Nucor Corporation pays a 0.82% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NUE | TGTX | |
|---|---|---|
Market Cap | $61.93B | $7.64B |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $59.06 |
52-Week Low | $131.78 | $26.94 |
Enterprise Value | $66.34B | $7.84B |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $272.28, down 0.85% on the day, as the steel producer shows mixed technical signals with a bullish moving average trend but overbought RSI readings. Fundamentally, the company delivered strong Q2 2026 earnings beats with EPS of $4.84 versus $4.46 expected, while revenue trends show recovery from 2024 lows. Analyst sentiment remains positive with 59% buy ratings and a $279.63 consensus target, though recent tariff developments and cyclical steel demand create headwinds.
The outlook for NUE appears cautiously optimistic with improving earnings momentum and favorable analyst coverage, though investors face risks from steel price volatility and macroeconomic pressures. The stock's current valuation at 21.7x P/E appears reasonable given the earnings recovery trajectory, but requires sustained operational execution to justify further upside beyond current resistance levels near $275.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
